Search review questions

Tranquil or asleep: Average sedation score ‐ by 1 hour Ramsay Sedation Scale · people with psychosis‐induced aggression

Global state: Needing restraints or seclusion ‐ by 12 hours · people with psychosis‐induced aggression

Adverse effects: Specific and serious adverse effect ‐ by 24 hours Central nervous system ‐ excessive sedation · people with psychosis‐induced aggression

Adverse effect: Specific ‐ Death · people with psychosis‐induced aggression

Service outcomes: Not discharged ‐ by 2 weeks · people with psychosis‐induced aggression

Specific behaviours: Average aggression score ‐ by 12 hours Overt Aggression Scale · people with psychosis‐induced aggression

Economics: Costs of care · people with psychosis‐induced aggression

Tranquil or asleep: Not tranquil or asleep ‐ by 30 mins · people with psychosis‐induced aggression

Adverse effects: Specific and serious adverse effects by 24 hours (not death) Central nervous system ‐ seizure · people with psychosis‐induced aggression

Global state: Needing restraints or seclusion ‐ by 12 hours · people with psychosis‐induced aggression

Adverse effects: Specific and serious adverse effect ‐ by 24 hours Central nervous system ‐ excessive sedation · people with psychosis‐induced aggression

Adverse effect: Specific ‐ Death · people with psychosis‐induced aggression

Service outcomes: Not discharged ‐ by 4 hours · people with psychosis‐induced aggression

Specific behaviours: Average aggression score · people with psychosis‐induced aggression

Economics: Costs of care · people with psychosis‐induced aggression

Tranquil or asleep: Not tranquil or asleep · people with psychosis‐induced aggression

Global state: Needing restraints or seclusion‐ by 2 hours · people with psychosis‐induced aggression

Adverse effect: Specific ‐ Death · people with psychosis‐induced aggression

Service outcomes: Not discharged ‐ · people with psychosis‐induced aggression

Adverse effect: Specific and serious ‐ Death · people with psychosis‐induced aggression

Specific behavioursAggression · people with psychosis‐induced aggression

Economics: Costs of care · people with psychosis‐induced aggression

Service outcomes: Not discharged ‐ by 2 weeks · people with psychosis‐induced aggression

Specific behaviours: Average aggression score ‐ by 12 hours Overt Aggression Scale · people with psychosis‐induced aggression

Economics: Costs of care · people with psychosis‐induced aggression

Tranquil or asleep: Not tranquil or asleep ‐ by 30 mins · people with psychosis‐induced aggression

Global state: Needing restraints or seclusion by 12 hours · people with psychosis‐induced aggression

Mental state: no clinically significant response in psychotic symptoms (defined by various scale total score change) ‐ short term (up to 12 weeks) ‐ defined by PANSS/BPRS <20% decline · patients with schizophrenia

Leaving the study early ‐ short term (up to 12 weeks) ‐ any reason · patients with schizophrenia

Global state: 2. no significant clinical improvement ‐ CGI, short term (up to 12 weeks) · patients with schizophrenia

Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks) ‐ general ‐ any significant EPS · patients with schizophrenia

Mental state: no clinically significant response in psychotic symptoms ‐ short term PANSS/BPRS < 20% decline · people with schizophrenia

Leaving the study early due to any reason ‐ short term · people with schizophrenia

Global state: no significant clinical improvement ‐ CGI short term · people with schizophrenia

Adverse effects: extrapyramidal ‐ short term · people with schizophrenia

Mental state: 1. General ‐ average endpoint score BPRS total scores · people with psychosis

Global state: general ‐ no clinically significant improvement · people with psychosis

General functioning: improved to an important degree · people with psychosis

Adverse effects: specific: extrapyramidal symptoms ‐ average endpoint scores parkinsonism SAS total · people with psychosis

Quality of life: improved to an important degree · people with psychosis

Mental state: 1. General ‐ average endpoint score ‐ short term ‐ only mifepristone BPRS total · people with psychosis

Mental state: 2. Specific ‐ negative symptoms ‐ average endpoint scores ‐ immediate PANSS negative subscale · people with psychosis

Global state: general ‐no clinically significant improvement ‐ data only for mifepristone < 30% improvement on BPRS · people with psychosis

General functioning: average endpoint scores ‐ data only for DHEA GAF/SOFA · people with psychosis

Adverse effects: 1. General ‐ overall number of events · people with psychosis

Adverse events: 2. Specific ‐ extrapyramidal symptoms ‐ average endpoint scores ‐ data only for DHEA SHRS total · people with psychosis

Mental state: 2. Specific ‐ depression ‐ average endpoint score HAMD total · people with psychosis

Quality of life: improved to an important degree · people with psychosis

Global state: 1. General ‐ no clinically significant improvement ‐ short term < 30% improvement on BPRS · people with psychosis

Global state: 2. Specific: positive ‐ no clinically significant improvement ‐ short term (< 50% improvement on BPRS PSS) · people with psychosis